# US 2003/0223974 A1 · Cellular trans-differentiation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0223974 A1
- Document ID: US20030223974A1
- Status: Published application
- Kind: A1
- Application number: 10/373,124
- Filed: 2003-02-24
- Published: 2003-12-04
- Earliest claimed: 2002-02-22
- Assignees: University of Florida Research Foundation, Inc.
- Inventors: Lijun Yang
- Web page: https://patentgrep.com/patent/US20030223974A1

## CPC

- C12N 5/0676: {Pancreatic cells}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N 2500/34: Sugars
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Highly purified hepatic stem cells are trans-differentiated into pancreatic endocrine hormone-producing cells by culturing them in vitro in a medium containing high levels of glucose. These trans-differentiated cells express insulin, glucagon, and pancreatic polypeptide, but not hepatocyte protein Hep-par. When stimulated with glucose, these cells synthesize and secrete insulin, a response enhanced by nicotinamide. Transplantation of these trans-differentiated cells into a hyperglycemic animal normalizes blood sugar levels in the animal.

## Claims

### Claim 1

A method for making cells having a pancreatic endocrine cell-like phenotype, the method comprising the steps of:
(a) providing hepatic stem cells; and
(b) culturing the hepatic stem cells in vitro under conditions that result in the trans-differentiation of the hepatic stem cells into cells having a pancreatic endocrine cell-like phenotype.

### Claim 2 (depends on 1)

The method of claim 1 wherein the step (b) of culturing the hepatic stem cells comprises culturing the cells in a medium comprising greater than 5.5 mM glucose.

### Claim 3 (depends on 2)

The method of claim 2, wherein the medium comprises at least 10 mM glucose.

### Claim 4 (depends on 2)

The method of claim 2, wherein the medium comprises RPMI 1640 supplemented with fetal calf serum.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cells having a pancreatic endocrine cell-like phenotype produce insulin, proinsulin, or pre-proinsulin.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cells having a pancreatic endocrine cell-like phenotype produce somatostatin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cells having a pancreatic endocrine cell-like phenotype produce glucagon.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cells having a pancreatic endocrine cell-like phenotype produce pancreatic polypeptide.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cells having a pancreatic endocrine cell-like phenotype contain higher levels of mRNA encoding a protein selected from the group consisting of insulin, somatostatin, glucagon, and pancreatic polypeptide than do the hepatic stems cells from which they were derived.

### Claim 10 (depends on 1)

Cells having a pancreatic endocrine cell-like phenotype made according to the method of claim 1.

### Claim 11 (depends on 10)

The cells of claim 10, wherein the cells produce insulin, proinsulin, or pre-proinsulin.

### Claim 12 (depends on 10)

The cells of claim 10, wherein the cells produce somatostatin.

### Claim 13 (depends on 10)

The cells of claim 10, wherein the cells produce glucagon.

### Claim 14 (depends on 10)

The cells of claim 10, wherein the cells produce pancreatic polypeptide.

### Claim 15 (depends on 10)

The cells of claim 10, wherein the cells contain higher levels of mRNA encoding a protein selected from the group consisting of insulin, somatostatin, glucagon, and pancreatic polypeptide than do the hepatic stems cells from which they were derived.

### Claim 16 (depends on 10)

A method of reducing a pancreatic endocrine hormone insufficiency in a subject, the method comprising the step of introducing into the subject a composition comprising the cells of claim 10 in an amount effective to reduce the pancreatic endocrine hormone insufficiency in the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cells produce insulin, proinsulin, or pre-proinsulin.

### Claim 18 (depends on 16)

The method of claim 16, wherein the cells produce somatostatin.

### Claim 19 (depends on 16)

The method of claim 16, wherein the cells produce glucagon.

### Claim 20 (depends on 16)

The method of claim 16, wherein the cells produce pancreatic polypeptide.

### Claim 21 (depends on 16)

The method of claim 16, wherein the cells contain higher levels of mRNA encoding a protein selected from the group consisting of insulin, somatostatin, glucagon, and pancreatic polypeptide than do the hepatic stems cells from which they were derived.

### Claim 22 (depends on 16)

The method of claim 16, wherein the cells are derived from hepatic stem cells obtained from the subject.

### Claim 23 (depends on 16)

The method of claim 16, wherein the cells are derived from hepatic stem cells not obtained from the subject.

### Claim 24 (depends on 16)

The method of claim 16, wherein the cells are introduced into the subject by implantation into a target tissue or organ.

### Claim 25 (depends on 24)

The method of claim 24, wherein the target tissue or organ is a liver.
